Concordia Healthcare Corp. closes $67.6 million bought deal financing

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./

TORONTO, March 11, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia") (TSX: CXR), is pleased to announce that it has closed its previously announced short form prospectus offering, on a "bought deal" basis, of 5,750,000 common shares (the "Common Shares") of Concordia, which includes the exercise by the Underwriters (as defined below) of an over-allotment option of 15%, for aggregate gross proceeds of $67,562,500 (the "Offering"). The Offering was completed at a price per Common Share of $11.75 by a syndicate of underwriters co-led by GMP Securities L.P. and Canaccord Genuity Corp. and including Barclays Capital Canada Inc., Beacon Securities Limited and Cormark Securities Inc.

About Concordia

Concordia is a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs and medical devices for the diabetic population. The company's legacy pharmaceutical business consists of an ADHD-treatment drug, Kapvay® (clonidine extended release tablets), Ulesfia® (benzyl alcohol) Lotion a Head Lice Treatment, and an Asthma-related medication, Orapred ODT® (prednisolone sodium phosphate orally disintegrating tablets). Concordia's Specialty Healthcare Distribution (SHD) division (Complete Medical Homecare) distributes medical supplies targeting diabetes and related conditions. Concordia's orphan division, Pinnacle, markets Photofrin® in the United States.

Concordia operates out of facilities in Oakville, Ontario, Lenexa, Kansas (near Kansas City, Missouri), Bannockburn, (near Chicago), Illinois and Bridgetown, Barbados.

SOURCE Concordia Healthcare Corp.